HBV therapy: Guidelines and open issues

Digestive and Liver Disease

Volumn 43, Issue SUPPL. 1, 2011, Pages

  Alberti, Alfredo ^a   Caporaso, Nicola ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antiviral therapy; Chronic hepatitis B; Interferon alpha; Nucleoside nucleotide analogs

Indexed keywords

ADEFOVIR; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL THERAPY; ARTICLE; CHRONIC DISEASE; DISEASE COURSE; DRUG POTENCY; HEPATITIS A; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY INJURY; LACTIC ACIDOSIS; LIVER CIRRHOSIS; LONG TERM CARE; MIXED INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT INDICATION; VIRUS INFECTION; VIRUS REACTIVATION;

HEPATITIS B, CHRONIC; HUMANS; ITALY; PRACTICE GUIDELINES AS TOPIC;

EID: 78650631585     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(10)60693-7     Document Type: Article

References (14)

1. Dienstag JL Hepatitis B virus infection. N Engl J Med 2008, 359:1486-1500.
2. Nafa S, Ahmed S, Tavan D, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000, 32:1078-1088.
3. Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001, 34:785-791.
4. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003, 36:687-696.
5. Ghany M, Liang TJ Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007, 132:1574-1585.
6. Zoulim F, Perrillo R Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008, 48(Suppl 1):S2-197.
7. Carosi G, Rizzetto M Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liver Dis 2008 Aug, 40(8):603-617.
8. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242.
9. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HbeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123-129.
10. Van Zonneveld M, Flink HJ, Verhey E, et al. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther 2005, 21:1163-1171.
11. Moucari R, Mackiewicz V, Lada O, et al. Early serum HbsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HbeAg-negative patients. Hepatology 2009, 49:1151-1157.
12. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009, 50:2001-2006.
13. Rodriguez-Nóvoa S, Alvarez E, Labarga P, et al. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010 Jul, 9(4):545-559.
14. Potthoff A, Manns MP, Wedemeyer H Treatment of HBV/HCV coinfection. Expert Opin Pharmacother 2010, 11(6):919-928.